share_log

HC Wainwright & Co. Maintains Buy on SpringWorks Therapeutics, Raises Price Target to $73

Benzinga ·  Nov 29, 2023 06:50

HC Wainwright & Co. analyst Robert Burns maintains SpringWorks Therapeutics (NASDAQ:SWTX) with a Buy and raises the price target from $64 to $73.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment